Literature DB >> 9736279

Angiotensin II modulates cellular functions of podocytes.

J Gloy1, A Henger, K G Fischer, R Nitschke, M Bleich, P Mundel, P Schollmeyer, R Greger, H Pavenstädt.   

Abstract

Angiotensin II modulates cellular functions of podocytes. The aim of this study was to examine the effects of angiotensin II (Ang II) on membrane voltage (Vm) and cytosolic calcium activity ([Ca2+]i) of rat podocytes. To approach better the in vivo situation, we have developed an experimental approach that allows podocytes to be studied in the intact microdissected glomerulus. Ang II depolarized podocytes in the glomerulus (EC50 15 nM, N = 49). Like podocytes in the glomerulus, podocytes in short-term culture also depolarized in response to Ang II (10 nM, N = 5). Ang II increased [Ca2+]i in podocytes in culture (EC50 3 nM, N = 229). In a solution with reduced extracellular [Ca2+] (10 microM), Ang II-mediated [Ca2+]i increase was significantly reduced by 60% +/- 20% (N = 12). Flufenamate, an inhibitor of nonselective ion channels, inhibited Ang II-mediated increase of [Ca2+]i (IC50 20 microM, N = 29). The Ang subtype 1 (AT1) receptor antagonist losartan inhibited both Ang II-mediated depolarization and [Ca2+]i increase in podocytes (N = 5 to 35). Our results support the concept that Ang II might influence podocyte function directly via an AT1 receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736279     DOI: 10.1046/j.1523-1755.1998.06736.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  8 in total

Review 1.  The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy.

Authors:  Raghu V Durvasula; Stuart J Shankland
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

2.  Mycophenolate mofetil inhibits hypertrophy and apoptosis of podocyte in vivo and in vitro.

Authors:  Wei Lv; Jingqiu Lou; Yan Zhang; Peiwen Lian; Dong Qi; Jianping Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Renin-angiotensin axis blockade reduces proteinuria in presymptomatic patients with familial FSGS.

Authors:  Lawrence Copelovitch; Marta Guttenberg; Martin R Pollak; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2007-05-25       Impact factor: 3.714

4.  Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.

Authors:  Takashi Naito; Li-Jun Ma; Haichun Yang; Yiqin Zuo; Yiwei Tang; Jee Young Han; Valentina Kon; Agnes B Fogo
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-30

Review 5.  Podocyte dysfunction in aging--related glomerulosclerosis.

Authors:  Marcello Camici; Angelo Carpi; Giuseppe Cini; Fabio Galetta; Nader Abraham
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

6.  Association of angiotensin-converting enzyme gene I/D polymorphism with steroid responsiveness in childhood nephrotic syndrome.

Authors:  P Prasun; N Prasad; G Tripathi; T Jafar; S Sharda; S Gulati; S Agrawal
Journal:  Indian J Nephrol       Date:  2011-01

Review 7.  Inhibition of RAS in diabetic nephropathy.

Authors:  Rabi Yacoub; Kirk N Campbell
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-04-15

Review 8.  Understanding Podocyte Biology to Develop Novel Kidney Therapeutics.

Authors:  Mark A Lal; Jaakko Patrakka
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-23       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.